Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FTB-918
- Development stage
- Preclinical
- Lead developer
- Fortitude Biomedicines
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
FTB-918 is a first-in-class, dual-targeting antibody fusion (biologic) designed to simultaneously deplete pathogenic TRBV9+ CD8+ T cells and neutralize IL-17A. Developed by Fortitude Biomedicines, it is being investigated for the treatment of axial spondyloarthritis (axSpA). By targeting both a cellular driver (TRBV9 T-cell receptor) and a key inflammatory cytokine (IL-17A) in a single molecule, FTB-918 aims to address multiple disease-causing pathways and improve therapeutic efficacy in patients who fail to achieve adequate disease control with standard therapies. As of late 2026, the drug is in preclinical development, with clinical entry expected in the first half of 2027.
02
Targets
IL-17A (Interleukin-17A)TRBV9 (T-cell receptor beta variable 9)
Beyond the preview
Go deeper on FTB-918.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FTB-918.